BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2021;21:36. [PMID: 34009478 DOI: 10.1007/s11910-021-01117-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Woopen C, Schleußner K, Akgün K, Ziemssen T. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Front Immunol 2021;12:701752. [PMID: 34234787 DOI: 10.3389/fimmu.2021.701752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Daripa B, Lucchese S. Varicella-Zoster Reactivation in a Non-immunized Elderly Multiple Sclerosis Patient While on Delayed-Release Dimethyl Fumarate With Grade 2 Lymphopenia and Profoundly Low CD4+ and CD8+ Cell Counts: A Case Report. Cureus. [DOI: 10.7759/cureus.22679] [Reference Citation Analysis]
3 Lucchini M, Del Giacomo P, De Arcangelis V, Nociti V, Bianco A, De Fino C, Presicce G, Cicia A, Carlomagno V, Mirabella M. The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. JPM 2022;12:591. [DOI: 10.3390/jpm12040591] [Reference Citation Analysis]